Skip to main content
Log in

Alendronate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two-arm study

  • Original Article
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

Our trial was a 3-year, open-label, prospective, comparative, clinical study comparing the effects of oral alendronate (ALN), 10 mg daily, and alfacalcidol (AC), 1 μg daily, on bone mineral density (BMD), fracture events, height, back pain, safety and tolerability in 134 men with established primary osteoporosis. All men received 500 mg calcium daily. BMD was measured at the lumbar spine and femoral neck using dual-energy X-ray absorptiometry (DXA). Spine radiographs were obtained at baseline and every 12 months thereafter, and were evaluated by a radiologist blinded to treatment assignment. At 3 years, AC-treated patients showed a significant mean increase of 3.5% in lumbar spine BMD, compared with a mean increase of 11.5% in men receiving ALN (p<0.0001 between groups). The corresponding increases in femoral neck BMD were 2.3% and 5.8% for the AC and ALN groups, respectively (p=0.0015 between groups). Over 3 years, new vertebral fractures occurred in 24.2% of the AC-treated patients and in 10.3% of the ALN-treated patients (p=0.040). ALN-treated patients also had a significantly lower height loss. There were no between-group differences regarding nonvertebral fractures or changes in back pain. Both therapies were well tolerated, with a compliance rate >90%. We conclude that although AC has significant effects on BMD, ALN has greater effects on BMD and fracture efficacy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1A,B.
Fig. 2.
Fig. 3.

Similar content being viewed by others

References

  1. Barrett-Connor E (1995) The economic and human costs of osteoporotic fracture. Am J Med 98 [Suppl 2A]:3S-8S

  2. Cooper C, Campion G, Melton LJ III (1992) Hip fractures in the elderly: a world-wide projection. Osteoporosis Int 2:285–289

    CAS  Google Scholar 

  3. O'Neill TW, Felsenberg D, Varlow J et al (1996) The prevalence of vertebral deformity in European men and women: the European Vertebral Osteoporosis Study. J Bone Miner Res 11:1010–1018

    PubMed  Google Scholar 

  4. Orwoll E, Ettinger M, Weiss S et al (2000) Alendronate for the treatment of osteoporosis in men. N Engl J Med 343:604–610

    CAS  PubMed  Google Scholar 

  5. Ringe JD, Faber H, Dorst A (2001) Alendronate treatment of established primary osteoporosis in men: results of a 2-year prospective study. J Clin Endocrinol Metab 86:5252–5255

    CAS  PubMed  Google Scholar 

  6. Ho YV, Frauman AG, Thomson W, Seeman E (2000) Effects of alendronate on bone density in men with primary and secondary osteoporosis. Osteoporosis Int 11:98–101

    CAS  Google Scholar 

  7. Tonino RP, Meunier PJ, Emkey R et al (2000) Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. J Clin Endocrinol Metab 85:3109–3115

    Google Scholar 

  8. Boivin GY, Chavassieux PM, Santora AC et al (2000) Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 27:687–694

    Google Scholar 

  9. Orwoll ES (1999) The prevention and therapy of osteoporosis in men. In: Orwoll ES (ed) Osteoporosis in men. Academic Press, London, pp 553–569

  10. Saag KG, Emkey R, Schnitzer TJ et al (1998) Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 339:292–299

    Article  CAS  PubMed  Google Scholar 

  11. Cohen S, Levy RM, Keller M et al (1999) Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 42:2309–2318

    Article  CAS  PubMed  Google Scholar 

  12. Liberman UA, Weiss SR, Broll J et al (1995) Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 333:1437–1443

    CAS  PubMed  Google Scholar 

  13. Khosla S, Melton LJ III, Atkinson EJ et al (1998) Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J Clin Endocrinol Metab 83:2266–2274

    CAS  PubMed  Google Scholar 

  14. Legrand E, Chappard D, Pascaretti C et al (2000) Trabecular bone microarchitecture, bone mineral density, and vertebral fractures in male osteoporosis. J Bone Miner Res 15:13–19

    CAS  PubMed  Google Scholar 

  15. Falahati-Nini A, Riggs BL, Atkinson EJ et al (2000) Relative contribution of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest 12:1553–1560

    Google Scholar 

  16. De Laet CEDH, Van Hout BA, Burger H et al Hip fracture prediction in elderly men and women: validation in the Rotterdam study. J Bone Miner Res 13:1587–1593

    PubMed  Google Scholar 

  17. Mussolino ME, Looker AC, Madans JH et al (1998) Risk factors for hip fracture in white men: the NHANES I epidemiologic follow-up study. J Bone Miner Res 13:918–924

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to J. D. Ringe.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ringe, J.D., Dorst, A., Faber, H. et al. Alendronate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two-arm study. Rheumatol Int 24, 110–113 (2004). https://doi.org/10.1007/s00296-003-0388-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-003-0388-y

Keywords

Navigation